D.Western Therapeutics Institute,Inc.is a biotechnology company that focuses on development of innovative new drags to serve patients worldwide.

Product Pipeline

Product Pipeline

As of Mar 2018

DWTI Product Pipeline


※1 The domestic pharmaceutical company have option rights in the whole world except Japan of H-1129, now the company is evaluating.
※2 K-134 has been targeted arteriosclerosis obliterans as indication, developed and completed phase 2 by Kowa Company, Ltd.. Meanwhile, Kowa is now considering another target disease.

pdficon_large544KB(Enlarge the above diagram)

GLANATEC® ophthalmic solution 0.4% ▶Learn more

WP-1303(H-1129) ▶Learn more

H-1337 ▶Learn more

K-134 ▶Learn more

DW-1002 ▶Learn more

Japan Innovative Therapeutics, Inc. Product Pipeline


pdficon_large108KB(Enlarge the above diagram)

D.Western Therapeutics Institute, Inc.
1-18-11, Nishiki, Naka-ku,
Nagoyashi, Aichi 460-0003 Japan
TEL 81+52-218-8785
Copyright © D.Western Therapeutics Institute, Inc. All Rights Reserved.